Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T83001
|
||||
Former ID |
TTDS00016
|
||||
Target Name |
Dopamine reuptake
|
||||
Synonyms |
Dopamine re-uptake
|
||||
Target Type |
Successful
|
||||
Disease | Attention deficit hyperactivity disorder; Severe mood disorders [ICD9: 296, 314.00, 314.01; ICD10: F30-F39, F90] | ||||
Anesthesia; Ocular disease [ICD9:338; ICD10: R20.0, H00-H59] | |||||
Attention deficit hyperactivity disorder; Depression; Cocaine addiction [ICD9: 303-304, 304.2, 311, 314.00, 314.01; ICD10: F10-F19, F14.2, F32, F90] | |||||
Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10: F32, F33, M32] | |||||
Neuropathic pain [ICD9: 356.0, 356.8; ICD10: G64, G90.0] | |||||
Obesity [ICD9: 278; ICD10: E66] | |||||
Severe mood disorders [ICD9: 296; ICD10: F30-F39] | |||||
Target Validation |
T83001
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Cocaine | Drug Info | Approved | Anesthesia; Ocular disease | [539436], [550681], [551871] |
Phenmetrazine | Drug Info | Approved | Obesity | [550743] | |
Bupropion+naltrexone | Drug Info | Phase 3 | Obesity | [532233] | |
DOV 21947 | Drug Info | Phase 2 | Severe mood disorders | [536580] | |
Amineptine | Drug Info | Withdrawn from market | Major depressive disorder | [551871] | |
DOV-216303 | Drug Info | Discontinued in Phase 2 | Severe mood disorders | [536580] | |
GSK372475 | Drug Info | Discontinued in Phase 2 | Attention deficit hyperactivity disorder; Severe mood disorders | [533085] | |
NS 2359 | Drug Info | Discontinued in Phase 2 | Attention deficit hyperactivity disorder; Depression; Cocaine addiction | [536580] | |
Radafaxine | Drug Info | Discontinued in Phase 2 | Major depressive disorder | [536295] | |
Radaxafine HCl | Drug Info | Discontinued in Phase 1 | Neuropathic pain | [536374] | |
Inhibitor | Amineptine | Drug Info | [538060] | ||
Bupropion+naltrexone | Drug Info | [536710] | |||
Cocaine | Drug Info | [537241] | |||
DOV 21947 | Drug Info | [536580] | |||
DOV-216303 | Drug Info | [536580] | |||
GSK372475 | Drug Info | [536580] | |||
Indatraline | Drug Info | [535184] | |||
NS 2359 | Drug Info | [536499] | |||
Phenmetrazine | Drug Info | [535503] | |||
Radafaxine | Drug Info | [536122], [536295] | |||
Radaxafine HCl | Drug Info | [536374] | |||
References | |||||
Ref 532233 | A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013 May;21(5):935-43. | ||||
Ref 533085 | Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. Drug Des Devel Ther. 2014 Dec 1;8:2321-32. | ||||
Ref 536580 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. | ||||
Ref 535184 | Effects of indatraline and buprenorphine on self-administration of speedball combinations of cocaine and heroin by rhesus monkeys. Neuropsychopharmacology. 2001 Jul;25(1):104-17. | ||||
Ref 535503 | Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7. | ||||
Ref 536122 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
Ref 536499 | Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34. | ||||
Ref 536580 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.